Vandetanib for the Management of Advanced Medullary Thyroid Cancer: A Real-World Multicenter Experience

BACKGROUND: Vandetanib is the most widely used tyrosine kinase inhibitor for the treatment of patients with advanced medullary thyroid cancer (MTC). However, only limited data regarding its use outside clinical trials are available. We aimed to evaluate the efficacy and safety of vandetanib in patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Mijin, Yoon, Jee Hee, Ahn, Jonghwa, Jeon, Min Ji, Kim, Hee Kyung, Lim, Dong Jun, Kang, Ho-Cheol, Kim, In Joo, Shong, Young Kee, Kim, Tae Yong, Kim, Bo Hyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Endocrine Society 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7520595/
https://www.ncbi.nlm.nih.gov/pubmed/32981301
http://dx.doi.org/10.3803/EnM.2020.687

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7520595/
https://www.ncbi.nlm.nih.gov/pubmed/32981301
http://dx.doi.org/10.3803/EnM.2020.687

Ejemplares similares